OLANZAPINE PAMOATE ANHYDROUS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H16O6.C17H20N4S
Molecular Weight	700.802
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of OLANZAPINE PAMOATE ANHYDROUS

Structure Search

SMILES

CN1CCN(CC1)C2=NC3=CC=CC=C3NC4=C2C=C(C)S4.OC(=O)C5=CC6=C(C=CC=C6)C(CC7=C8C=CC=CC8=CC(C(O)=O)=C7O)=C5O

InChI

InChIKey=IUDQMMSLVSVGDZ-UHFFFAOYSA-N

InChI=1S/C23H16O6.C17H20N4S/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h1-10,24-25H,11H2,(H,26,27)(H,28,29);3-6,11,19H,7-10H2,1-2H3

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020592s067,021086s043,021253s056lbl.pdf
Curator's Comment: description was created based on several sources, including http://www.priory.com/focus3.htm

Olanzapine is a novel antipsychotic agent marketed by Lilly & Co. It has a pleotrophic pharmacology and affects dopaminergic, serotonergic, muscarinic and adrenergic activities. Olanzapine is used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression) in adults and children who are at least 13 years old. Olanzapine is sometimes used together with other antipsychotic medications or antidepressants. The mechanism of action of olanzapine, as with other drugs having efficacy in schizophrenia, is unknown. However, it has been proposed that this drug’s efficacy in schizophrenia is mediated through a combination of dopamine and serotonin type 2 (5HT2) antagonism. The mechanism of action of olanzapine in the treatment of acute manic or mixed episodes associated with bipolar I disorder is unknown. Olanzapine treatment led to rapid phosphorylation of kinases from all three pathways in PC12 cells. Phosphorylation of Akt was blocked with selective inhibitors (wortmannin and LY294002), which implicates phosphoinositide 3-kinase (PI3K) in the signaling cascade. Short-term mitogenic effects of olanzapine were abolished with a selective inhibitor of Akt, but not by inhibition of the ERK pathway. Olanzapine is metabolized by the cytochrome P450 system; principally by isozyme 1A2 and to a lesser extent by 2D6. By these mechanisms more than 40% of the oral dose, on average, is removed by the hepatic first-pass effect. Drugs or agents that increase the activity of CYP1A2, notably tobacco smoke, may significantly increase hepatic first-pass clearance of Olanzapine; conversely, drugs which inhibit 1A2 activity (examples: Ciprofloxacin, Fluvoxamine) may reduce Olanzapine clearance. The most common side effects appear to be somnolence and weight gain. About 11% of patients gain weight -especially if on a high starting dose and if they were underweight pre-treatment. Sexual dysfunction is a problem for many patients, although sexual dysfunction in schizophrneia does not appear to be primarily attributable to drugs.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine D2 receptor 297 Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15358979	Antagonist 2778
Serotonin 2a (5-HT2a) receptor 231 Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15358979	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Schizophrenia 298 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020592s067,021086s043,021253s056lbl.pdf	Primary		Approved 8429	ZYPREXA Approved Use Olanzapine orally disintegrating tablets, USP are atypical antipsychotic indicated: As oral formulation for the: Treatment of schizophrenia. (1.1) Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. (14.1) Adolescents (ages 13 to 17): Efficacy was established in one 6-week trial in patients with schizophrenia (14.1). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. (1.1) Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. (1.2) Adults: Efficacy was established in three clinical trials in patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one maintenance trial. (14.2) Adolescents (ages 13 to 17): Efficacy was established in one 3-week trial in patients with manic or mixed episodes associated with bipolar I disorder (14.2). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. (1.2) Medication therapy for pediatric patients with schizophrenia or bipolar I disorder should be undertaken only after a thorough diagnostic evaluation and with careful consideration of the potential risks. (1.3) Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar I disorder. (1.2) Efficacy was established in two 6-week clinical trials in adults (14.2). Maintenance efficacy has not been systematically evaluated. As O lanzapine Orally Disintegrating Tablets, USP and Fluoxetine in Combination for the: Treatment of depressive episodes associated with bipolar I disorder. (1.5) Efficacy was established with Symbyax* (olanzapine and fluoxetine in combination); refer to the product label for Symbyax*. 1.1 Schizophrenia Olanzapine orally disintegrating tablets, USP are indicated for the treatment of schizophrenia. Efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. In adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial [see Clinical Studies (14.1) Launch Date 1996
Bipolar I disorder 17 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020592s067,021086s043,021253s056lbl.pdf	Primary		Approved 8429	ZYPREXA Approved Use Olanzapine orally disintegrating tablets, USP are atypical antipsychotic indicated: As oral formulation for the: Treatment of schizophrenia. (1.1) Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. (14.1) Adolescents (ages 13 to 17): Efficacy was established in one 6-week trial in patients with schizophrenia (14.1). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. (1.1) Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. (1.2) Adults: Efficacy was established in three clinical trials in patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one maintenance trial. (14.2) Adolescents (ages 13 to 17): Efficacy was established in one 3-week trial in patients with manic or mixed episodes associated with bipolar I disorder (14.2). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. (1.2) Medication therapy for pediatric patients with schizophrenia or bipolar I disorder should be undertaken only after a thorough diagnostic evaluation and with careful consideration of the potential risks. (1.3) Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar I disorder. (1.2) Efficacy was established in two 6-week clinical trials in adults (14.2). Maintenance efficacy has not been systematically evaluated. As O lanzapine Orally Disintegrating Tablets, USP and Fluoxetine in Combination for the: Treatment of depressive episodes associated with bipolar I disorder. (1.5) Efficacy was established with Symbyax* (olanzapine and fluoxetine in combination); refer to the product label for Symbyax*. 1.1 Schizophrenia Olanzapine orally disintegrating tablets, USP are indicated for the treatment of schizophrenia. Efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. In adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial [see Clinical Studies (14.1) Launch Date 1996

C_max

Value	Dose	Co-administered	Analyte	Population
17.3 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12895191	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		OLANZAPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
712 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12895191	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		OLANZAPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
28.7 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12895191	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		OLANZAPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33564555	unhealthy, 20 years n = 1 Health Status: unhealthy Condition: paranoid schizophrenia Age Group: 20 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/33564555	Disc. AE: Rhabdomyolysis... AEs leading to discontinuation/dose reduction: Rhabdomyolysis (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/33564555
5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21086lbl.pdf	unhealthy, 83 years (range: 61-97 years) n = 65 Health Status: unhealthy Condition: psychiatric symptoms Age Group: 83 years (range: 61-97 years) Sex: M+F Population Size: 65 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21086lbl.pdf	Disc. AE: Accidental injury, Somnolence... AEs leading to discontinuation/dose reduction: Accidental injury (1%) Somnolence (3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21086lbl.pdf
300 mg 1 times / day multiple, oral Highest studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf	unhealthy, adult n = 67 Health Status: unhealthy Age Group: adult Population Size: 67 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf	Other AEs: Drowsiness, Slurred speech... Other AEs: Drowsiness Slurred speech Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
40 mg 1 times / day multiple, oral Highest studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf	unhealthy, adult n = 200 Health Status: unhealthy Condition: schizophrenia \|schizoaffective disorder Age Group: adult Sex: M+F Population Size: 200 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf	Other AEs: Dizziness... Other AEs: Dizziness (6.6%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
2 g single, oral Overdose Dose: 2 g Route: oral Route: single Dose: 2 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf	unhealthy, adult n = 1 Health Status: unhealthy Age Group: adult Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf	Disc. AE: Weight gain... AEs leading to discontinuation/dose reduction: Weight gain (0.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf	unhealthy, old Health Status: unhealthy Condition: DEMENTIA-RELATED PSYCHOSIS Age Group: old Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf	Other AEs: Adverse event... Other AEs: Adverse event (grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf

AEs

AE	Significance	Dose	Population
Rhabdomyolysis	1 patient Disc. AE	10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33564555	unhealthy, 20 years n = 1 Health Status: unhealthy Condition: paranoid schizophrenia Age Group: 20 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/33564555
Accidental injury	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21086lbl.pdf	unhealthy, 83 years (range: 61-97 years) n = 65 Health Status: unhealthy Condition: psychiatric symptoms Age Group: 83 years (range: 61-97 years) Sex: M+F Population Size: 65 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21086lbl.pdf
Somnolence	3% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21086lbl.pdf	unhealthy, 83 years (range: 61-97 years) n = 65 Health Status: unhealthy Condition: psychiatric symptoms Age Group: 83 years (range: 61-97 years) Sex: M+F Population Size: 65 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21086lbl.pdf
Drowsiness		300 mg 1 times / day multiple, oral Highest studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf	unhealthy, adult n = 67 Health Status: unhealthy Age Group: adult Population Size: 67 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
Slurred speech		300 mg 1 times / day multiple, oral Highest studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf	unhealthy, adult n = 67 Health Status: unhealthy Age Group: adult Population Size: 67 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
Dizziness	6.6%	40 mg 1 times / day multiple, oral Highest studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf	unhealthy, adult n = 200 Health Status: unhealthy Condition: schizophrenia \|schizoaffective disorder Age Group: adult Sex: M+F Population Size: 200 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
Weight gain	0.2% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
Adverse event	grade 5	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf	unhealthy, old Health Status: unhealthy Condition: DEMENTIA-RELATED PSYCHOSIS Age Group: old Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587 substrate 1737	inhibitor 1767 substrate 1037	inhibitor 1852 substrate 1217	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2C19 1478 BSEP 402	CYP1A2 1054 FMO 35 P-gp 1537 BCRP 561 UGT2B10 127 UGT1A4 347 CYP2C19 991 CYP2E1 667	FATP2 5

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020592_Original_Approval_Pkg%20.pdf Page: 310.0	moderate [Ki 36 uM]
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020592_Original_Approval_Pkg%20.pdf Page: 310.0	moderate [Ki 491 uM]	no (co-administration study) Comment: olanzapine has no effect on diazepam or N-desmethyldiazepam Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020592_Original_Approval_Pkg%20.pdf Page: 310.0
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020592_Original_Approval_Pkg%20.pdf Page: 310.0	moderate [Ki 715 uM]	no (co-administration study) Comment: olanzapine has no effect on warfarin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020592_Original_Approval_Pkg%20.pdf Page: 310.0
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020592_Original_Approval_Pkg%20.pdf Page: 310.0	moderate [Ki 89 uM]	no (co-administration study) Comment: olanzapine has no effect on imiprazine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020592_Original_Approval_Pkg%20.pdf Page: 310.0
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020592_Original_Approval_Pkg%20.pdf Page: 310.0	moderate [Ki 920 uM]	no (co-administration study) Comment: olanzapine has no effect on diazepam or N-desmethyldiazepam Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020592_Original_Approval_Pkg%20.pdf Page: 310.0
BSEP 403	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/22961681/	weak [IC50 54.57 uM]
OCTN2 71	supressor 155 Sources: https://pubmed.ncbi.nlm.nih.gov/31437515/	yes [IC50 1.06 uM]
FATP2 5	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/31437515/	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020639ap_Seroquel_phrmrP1.pdf Page: 66.0	no
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020639ap_Seroquel_phrmrP1.pdf Page: 66.0	no
CYP2E1 667	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020639ap_Seroquel_phrmrP1.pdf Page: 66.0	no
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020592_Original_Approval_Pkg%20.pdf Page: 308.0	weak	weak (co-administration study) Comment: in vivo; imiprazine increases olanzapine exposure by 19% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020592_Original_Approval_Pkg%20.pdf Page: 308.0
BCRP 561	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18834354/	yes [Ki >1000 uM]
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020639ap_Seroquel_phrmrP1.pdf Page: 66.0	yes
FMO 35	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020592_Original_Approval_Pkg%20.pdf Page: 308.0	yes
P-gp 1537	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21843066/	yes
UGT1A4 347	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/12404680/	yes
UGT2B10 127	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21750471/	yes
CYP1A2 1054	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022173s036lbl.pdf Page: 19, 20	yes	yes (co-administration study) Comment: carbamazepine increases olanzapine clearance by 50%; fluoxetine increased olanzapine Cmax and AUC; omeprazole and rifampin may increase olanzapine clearance Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022173s036lbl.pdf Page: 19, 20

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://pubmed.ncbi.nlm.nih.gov/12873512/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:7735	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7735
ChemicalBook	CB04188690	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB04188690
ChemicalBook	CB34188691	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB34188691
ChemicalBook	CB52743465	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB52743465
ChemicalBook	CB64188692	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB64188692
ChemicalBook	CB6755515	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6755515
MolPort	MolPort-002-885-845	https://www.molport.com/shop/molecule-link/MolPort-002-885-845
Selleck Chemicals	Olanzapine(Zyprexa)	http://www.selleckchem.com/products/Olanzapine(Zyprexa).html
ZINC	ZINC000052957434	http://zinc15.docking.org/substances/ZINC000052957434
eMolecules	902226	https://www.emolecules.com/cgi-bin/more?vid=902226

PubMed

Title	Date	PubMed
In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine.	1999 Apr 26	10482380
Preferential inhibition of dizocilpine-induced hyperlocomotion by olanzapine.	1999 Feb 26	10096763
Interaction between olanzapine and haloperidol.	1999 Jun	10350035
Olanzapine-induced obsessive-compulsive disorder.	1999 May	10327925
Worsening of motor features of parkinsonism with olanzapine.	1999 Nov	10584679
Hypomania-like syndrome induced by olanzapine.	1999 Nov	10565806
Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine.	1999 Oct	10505594
Brain SPECT imaging in Huntington's disease before and after therapy with olanzapine. Case report.	1999 Sep	10751925
Use of olanzapine in hereditary coproporphyria.	1999 Sep-Oct	10479951
D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.	2000	11198054
Esotropia associated with olanzapine.	2000 Aug	10917412
[Psychotic syndrome after withdrawal of cyproheptadine: remission with olanzapine].	2000 Jul-Aug	11116800
Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.	2000 Jun	10831489
Adverse effects of high-dose olanzapine in treatment-refractory schizophrenia.	2000 Jun	10831029
Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.	2000 Nov	11147933
Neuroleptic malignant syndrome associated with olanzapine therapy: a case report.	2000 Nov	11074330
A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder.	2000 Sep	11030483
Olanzapine and obsessive-compulsive symptoms.	2000 Sep	10974610
Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.	2001	11232753
Weight change and atypical antipsychotic treatment in patients with schizophrenia.	2001	11232752
An efficacy analysis of olanzapine treatment data in schizophrenia patients with catatonic signs and symptoms.	2001	11232748
Antipsychotic medications and the elderly: effects on cognition and implications for use.	2001	11232738
Olanzapine: an updated review of its use in the management of schizophrenia.	2001	11217867
Treatment of psychogenic polydipsia: comparison of risperidone and olanzapine, and the effects of an adjunctive angiotensin-II receptor blocking drug (irbesartan).	2001 Feb	11270459
Tolerability and effectiveness of atypical antipsychotics in male geriatric inpatients.	2001 Feb	11241729
New onset diabetes and atypical antipsychotics.	2001 Feb	11226809
Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal.	2001 Feb	11221497
Olanzapine and hypertriglyceridemia.	2001 Feb	11211361
Screening for detection of new antidepressants, neuroleptics, hypnotics, and their metabolites in urine by GC-MS developed using rat liver microsomes.	2001 Feb	11206046
Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine.	2001 Feb	11199953
Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial.	2001 Feb	11199942
Repeated episodes of hypothermia in a subject treated with haloperidol, levomepromazine, olanzapine, and thioridazine.	2001 Feb	11199936
Atypical antipsychotics and cardiovascular risk in schizophrenic patients.	2001 Feb	11199934
Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways.	2001 Feb	11180502
Bodyweight gain with atypical antipsychotics. A comparative review.	2001 Jan	11219487
Olanzapine-induced leukopenia with human leukocyte antigen profiling.	2001 Jan	11195261
Effect of chronic olanzapine treatment on striatal synaptic organization.	2001 Jan	11071704
Consistency of atypical antipsychotic superiority to placebo in recent clinical trials.	2001 Jan 1	11163781
[Olanzapine and pregnancy].	2001 Jan 21	11217163
Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum.	2001 Jan 26	11165224
Olanzapine-lnduced hyperglycemic nonketonic coma.	2001 Mar	11261526
5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release.	2001 Mar	11238736
Low blood glucose and olanzapine.	2001 Mar	11230004
Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.	2001 Mar	11229973
Electrooxidation potential as a tool in the early screening for new safer clozapine-like analogues.	2001 Mar 1	11262087
Quantitative determination of olanzapine in rat brain tissue by high-performance liquid chromatography with electrochemical detection.	2001 Mar 5	11254198

Patents

Sample Use Guides

In Vivo Use Guide

Schizophrenia: Adults: Oral olanzapine should be administered on a once-a-day schedule without regard to meals, generally beginning with 5 to 10 mg initially, with a target dose of 10 mg/day within several days. Further dosage adjustments, if indicated, should generally occur at intervals of not less than 1 week, since steady state for olanzapine would not be achieved for approximately 1 week in the typical patient. Adolescents: Oral olanzapine should be administered on a once-a-day schedule without regard to meals with a recommended starting dose of 2.5 or 5 mg, with a target dose of 10 mg/day. Efficacy in adolescents with schizophrenia was demonstrated based on a flexible dose range of 2.5 to 20 mg/day in clinical trials, with a mean modal dose of 12.5 mg/day (mean dose of 11.1 mg/day). Bipolar I Disorder (Manic or Mixed Episodes): Adults: Oral olanzapine should be administered on a once-a-day schedule without regard to meals, generally beginning with 10 or 15 mg. Dosage adjustments, if indicated, should generally occur at intervals of not less than 24 hours, reflecting the procedures in the placebo-controlled trials. Adolescents: Oral olanzapine should be administered on a once-a-day schedule without regard to meals with a recommended starting dose of 2.5 or 5 mg, with a target dose of 10 mg/day. Efficacy in adolescents with bipolar I disorder (manic or mixed episodes) was demonstrated based on a flexible dose range of 2.5 to 20 mg/day in clinical trials, with a mean modal dose of 10.7 mg/day (mean dose of 8.9 mg/day). IntraMuscular: Agitation Associated with Schizophrenia and Bipolar I Mania: The efficacy of intramuscular olanzapine for injection in controlling agitation in these disorders was demonstrated in a dose range of 2.5 mg to 10 mg.

Route of Administration: Other

In Vitro Use Guide

Unknown

Name

Type

Language

OLANZAPINE PAMOATE ANHYDROUS

Common Name

English

2-NAPHTHALENECARBOXYLIC ACID, 4,4'-METHYLENEBIS(3-HYDROXY-, COMPD. WITH 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO(2,3-B)(1,5)BENZODIAZEPINE (1:1)

Common Name

English

OLANZAPINE EMBONATE

Common Name

English

OLANZAPINE (AS EMBONATE)

Common Name

English

2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO(2,3-B)(1,5)BENZODIAZEPINE EMBONATE

Common Name

English

Code System Code Type Description

SMS_ID

100000124353